Biosimulation Market Size, Share, and Trends 2025 to 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Biosimulation Market 

5.1. COVID-19 Landscape: Biosimulation Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Biosimulation Market, By Product

8.1. Biosimulation Market, by Product

8.1.1. Software

8.1.1.1. Market Revenue and Forecast

8.1.2. Services

8.1.2.1. Market Revenue and Forecast

Chapter 9. Global Biosimulation Market, By Application 

9.1. Biosimulation Market, by Application 

9.1.1. Drug Discovery & Development

9.1.1.1. Market Revenue and Forecast

9.1.2. Disease Modeling

9.1.2.1. Market Revenue and Forecast

9.1.3. Other (Precision Medicine, Toxicology, etc.)

9.1.3.1. Market Revenue and Forecast

Chapter 10. Global Biosimulation Market, By Therapeutic Area

10.1. Biosimulation Market, by Therapeutic Area

10.1.1. Oncology

10.1.1.1. Market Revenue and Forecast

10.1.2. Cardiovascular Disease

10.1.2.1. Market Revenue and Forecast

10.1.3. Infectious Disease

10.1.3.1. Market Revenue and Forecast

10.1.4. Neurological Disorders

10.1.4.1. Market Revenue and Forecast

10.1.5. Others

10.1.5.1. Market Revenue and Forecast

Chapter 11. Global Biosimulation Market, By Deployment Model

11.1. Biosimulation Market, by Deployment Model

11.1.1. Cloud-based

11.1.1.1. Market Revenue and Forecast

11.1.2. On-premise

11.1.2.1. Market Revenue and Forecast

11.1.3. Hybrid Model

11.1.3.1. Market Revenue and Forecast

Chapter 12. Global Biosimulation Market, By Pricing Model

12.1. Biosimulation Market, by Pricing Model

12.1.1. License-based Model

12.1.1.1. Market Revenue and Forecast

12.1.2. Subscription-based Model

12.1.2.1. Market Revenue and Forecast

12.1.3. Service-based Model

12.1.3.1. Market Revenue and Forecast

12.1.4. Pay Per Use Model

12.1.4.1. Market Revenue and Forecast

Chapter 13. Global Biosimulation Market, By End Use

13.1. Biosimulation Market, by End Use

13.1.1. Life Sciences Companies

13.1.1.1. Market Revenue and Forecast

13.1.2. Academic Research Institutions

13.1.2.1. Market Revenue and Forecast

13.1.3. Others (Regulatory Authorities, etc.)

13.1.3.1. Market Revenue and Forecast

Chapter 14. Global Biosimulation Market, Regional Estimates and Trend Forecast

14.1. North America

14.1.1. Market Revenue and Forecast, by Product

14.1.2. Market Revenue and Forecast, by Application 

14.1.3. Market Revenue and Forecast, by Therapeutic Area

14.1.4. Market Revenue and Forecast, by Deployment Model

14.1.5. Market Revenue and Forecast, by Pricing Model

14.1.6. Market Revenue and Forecast, by End Use

14.1.7. U.S.

14.1.7.1. Market Revenue and Forecast, by Product

14.1.7.2. Market Revenue and Forecast, by Application 

14.1.7.3. Market Revenue and Forecast, by Therapeutic Area

14.1.7.4. Market Revenue and Forecast, by Deployment Model

14.1.8. Market Revenue and Forecast, by Pricing Model

14.1.8.1. Market Revenue and Forecast, by End Use  

14.1.9. Rest of North America

14.1.9.1. Market Revenue and Forecast, by Product

14.1.9.2. Market Revenue and Forecast, by Application 

14.1.9.3. Market Revenue and Forecast, by Therapeutic Area

14.1.9.4. Market Revenue and Forecast, by Deployment Model

14.1.10. Market Revenue and Forecast, by Pricing Model

14.1.11. Market Revenue and Forecast, by End Use

14.1.11.1.

14.2. Europe

14.2.1. Market Revenue and Forecast, by Product

14.2.2. Market Revenue and Forecast, by Application 

14.2.3. Market Revenue and Forecast, by Therapeutic Area

14.2.4. Market Revenue and Forecast, by Deployment Model  

14.2.5. Market Revenue and Forecast, by Pricing Model

14.2.6. Market Revenue and Forecast, by End Use

14.2.7.

14.2.8. UK

14.2.8.1. Market Revenue and Forecast, by Product

14.2.8.2. Market Revenue and Forecast, by Application 

14.2.8.3. Market Revenue and Forecast, by Therapeutic Area

14.2.9. Market Revenue and Forecast, by Deployment Model  

14.2.10. Market Revenue and Forecast, by Pricing Model

14.2.10.1. Market Revenue and Forecast, by End Use  

14.2.11. Germany

14.2.11.1. Market Revenue and Forecast, by Product

14.2.11.2. Market Revenue and Forecast, by Application 

14.2.11.3. Market Revenue and Forecast, by Therapeutic Area

14.2.12. Market Revenue and Forecast, by Deployment Model

14.2.13. Market Revenue and Forecast, by Pricing Model

14.2.14. Market Revenue and Forecast, by End Use

14.2.14.1.

14.2.15. France

14.2.15.1. Market Revenue and Forecast, by Product

14.2.15.2. Market Revenue and Forecast, by Application 

14.2.15.3. Market Revenue and Forecast, by Therapeutic Area

14.2.15.4. Market Revenue and Forecast, by Deployment Model

14.2.16. Market Revenue and Forecast, by Pricing Model

14.2.16.1. Market Revenue and Forecast, by End Use

14.2.17. Rest of Europe

14.2.17.1. Market Revenue and Forecast, by Product

14.2.17.2. Market Revenue and Forecast, by Application 

14.2.17.3. Market Revenue and Forecast, by Therapeutic Area

14.2.17.4. Market Revenue and Forecast, by Deployment Model

14.2.18. Market Revenue and Forecast, by Pricing Model

14.2.18.1. Market Revenue and Forecast, by End Use

14.3. APAC

14.3.1. Market Revenue and Forecast, by Product

14.3.2. Market Revenue and Forecast, by Application 

14.3.3. Market Revenue and Forecast, by Therapeutic Area

14.3.4. Market Revenue and Forecast, by Deployment Model

14.3.5. Market Revenue and Forecast, by Pricing Model

14.3.6. Market Revenue and Forecast, by End Use

14.3.7. India

14.3.7.1. Market Revenue and Forecast, by Product

14.3.7.2. Market Revenue and Forecast, by Application 

14.3.7.3. Market Revenue and Forecast, by Therapeutic Area

14.3.7.4. Market Revenue and Forecast, by Deployment Model

14.3.8. Market Revenue and Forecast, by Pricing Model

14.3.9. Market Revenue and Forecast, by End Use

14.3.10. China

14.3.10.1. Market Revenue and Forecast, by Product

14.3.10.2. Market Revenue and Forecast, by Application 

14.3.10.3. Market Revenue and Forecast, by Therapeutic Area

14.3.10.4. Market Revenue and Forecast, by Deployment Model

14.3.11. Market Revenue and Forecast, by Pricing Model

14.3.11.1. Market Revenue and Forecast, by End Use

14.3.12. Japan

14.3.12.1. Market Revenue and Forecast, by Product

14.3.12.2. Market Revenue and Forecast, by Application 

14.3.12.3. Market Revenue and Forecast, by Therapeutic Area

14.3.12.4. Market Revenue and Forecast, by Deployment Model

14.3.12.5. Market Revenue and Forecast, by Pricing Model

14.3.12.6. Market Revenue and Forecast, by End Use

14.3.13. Rest of APAC

14.3.13.1. Market Revenue and Forecast, by Product

14.3.13.2. Market Revenue and Forecast, by Application 

14.3.13.3. Market Revenue and Forecast, by Therapeutic Area

14.3.13.4. Market Revenue and Forecast, by Deployment Model

14.3.13.5. Market Revenue and Forecast, by Pricing Model

14.3.13.6. Market Revenue and Forecast, by End Use

14.4. MEA

14.4.1. Market Revenue and Forecast, by Product

14.4.2. Market Revenue and Forecast, by Application 

14.4.3. Market Revenue and Forecast, by Therapeutic Area

14.4.4. Market Revenue and Forecast, by Deployment Model

14.4.5. Market Revenue and Forecast, by Pricing Model

14.4.6. Market Revenue and Forecast, by End Use

14.4.7. GCC

14.4.7.1. Market Revenue and Forecast, by Product

14.4.7.2. Market Revenue and Forecast, by Application 

14.4.7.3. Market Revenue and Forecast, by Therapeutic Area

14.4.7.4. Market Revenue and Forecast, by Deployment Model

14.4.8. Market Revenue and Forecast, by Pricing Model

14.4.9. Market Revenue and Forecast, by End Use

14.4.10. North Africa

14.4.10.1. Market Revenue and Forecast, by Product

14.4.10.2. Market Revenue and Forecast, by Application 

14.4.10.3. Market Revenue and Forecast, by Therapeutic Area

14.4.10.4. Market Revenue and Forecast, by Deployment Model

14.4.11. Market Revenue and Forecast, by Pricing Model

14.4.12. Market Revenue and Forecast, by End Use

14.4.13. South Africa

14.4.13.1. Market Revenue and Forecast, by Product

14.4.13.2. Market Revenue and Forecast, by Application 

14.4.13.3. Market Revenue and Forecast, by Therapeutic Area

14.4.13.4. Market Revenue and Forecast, by Deployment Model

14.4.13.5. Market Revenue and Forecast, by Pricing Model

14.4.13.6. Market Revenue and Forecast, by End Use

14.4.14. Rest of MEA

14.4.14.1. Market Revenue and Forecast, by Product

14.4.14.2. Market Revenue and Forecast, by Application 

14.4.14.3. Market Revenue and Forecast, by Therapeutic Area

14.4.14.4. Market Revenue and Forecast, by Deployment Model

14.4.14.5. Market Revenue and Forecast, by Pricing Model

14.4.14.6. Market Revenue and Forecast, by End Use

14.5. Latin America

14.5.1. Market Revenue and Forecast, by Product

14.5.2. Market Revenue and Forecast, by Application 

14.5.3. Market Revenue and Forecast, by Therapeutic Area

14.5.4. Market Revenue and Forecast, by Deployment Model

14.5.5. Market Revenue and Forecast, by Pricing Model

14.5.6. Market Revenue and Forecast, by End Use

14.5.7. Brazil

14.5.7.1. Market Revenue and Forecast, by Product

14.5.7.2. Market Revenue and Forecast, by Application 

14.5.7.3. Market Revenue and Forecast, by Therapeutic Area

14.5.7.4. Market Revenue and Forecast, by Deployment Model

14.5.8. Market Revenue and Forecast, by Pricing Model

14.5.8.1. Market Revenue and Forecast, by End Use

14.5.9. Rest of LATAM

14.5.9.1. Market Revenue and Forecast, by Product

14.5.9.2. Market Revenue and Forecast, by Application 

14.5.9.3. Market Revenue and Forecast, by Therapeutic Area

14.5.9.4. Market Revenue and Forecast, by Deployment Model

14.5.9.5. Market Revenue and Forecast, by Pricing Model

14.5.9.6. Market Revenue and Forecast, by End Use

Chapter 15. Company Profiles

15.1. Biovia

15.1.1. Company Overview

15.1.2. Product Offerings

15.1.3. Financial Performance

15.1.4. Recent Initiatives

15.2. Certara

15.2.1. Company Overview

15.2.2. Product Offerings

15.2.3. Financial Performance

15.2.4. Recent Initiatives

15.3. Compugen Inc.

15.3.1. Company Overview

15.3.2. Product Offerings

15.3.3. Financial Performance

15.3.4. Recent Initiatives

15.4. Genedata

15.4.1. Company Overview

15.4.2. Product Offerings

15.4.3. Financial Performance

15.4.4. Recent Initiatives

15.5. In Silico Biosciences, Inc.

15.5.1. Company Overview

15.5.2. Product Offerings

15.5.3. Financial Performance

15.5.4. Recent Initiatives

15.6. Leadscope Inc.

15.6.1. Company Overview

15.6.2. Product Offerings

15.6.3. Financial Performance

15.6.4. Recent Initiatives

15.7. Pharmaceutical Product Development, LLC.

15.7.1. Company Overview

15.7.2. Product Offerings

15.7.3. Financial Performance

15.7.4. Recent Initiatives

15.8. Schrödinger, LLC.

15.8.1. Company Overview

15.8.2. Product Offerings

15.8.3. Financial Performance

15.8.4. Recent Initiatives

15.9. Simulations Plus, Inc.

15.9.1. Company Overview

15.9.2. Product Offerings

15.9.3. Financial Performance

15.9.4. Recent Initiatives

15.10. DassaultSystemes

15.10.1. Company Overview

15.10.2. Product Offerings

15.10.3. Financial Performance

15.10.4. Recent Initiatives

Chapter 16. Research Methodology

16.1. Primary Research

16.2. Secondary Research

16.3. Assumptions

Chapter 17. Appendix

17.1. About Us

17.2. Glossary of Terms